CreativeOne Wealth LLC Purchases 8,905 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• CreativeOne Wealth LLC increased its holdings in Lantheus Holdings, Inc. by 124.1%, acquiring an additional 8,905 shares, bringing their total ownership to 16,080 shares valued at approximately $1.57 million.
• Insiders have sold a total of 6,838,066 shares of Lantheus, worth nearly $384 million, indicating significant insider divestment during the past quarter.
• Lantheus's recent quarterly earnings showed a reported $1.57 EPS, missing analyst expectations and marking a 4.1% decline in revenue compared to the previous year.

CreativeOne Wealth LLC raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 124.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,080 shares of the medical equipment provider's stock after buying an additional 8,905 shares during the period. CreativeOne Wealth LLC's holdings in Lantheus were worth $1,569,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in LNTH. Epoch Investment Partners Inc. purchased a new stake in shares of Lantheus during the first quarter worth about $35,548,000. Comerica Bank boosted its holdings in shares of Lantheus by 14.7% during the first quarter. Comerica Bank now owns 304,160 shares of the medical equipment provider's stock worth $29,686,000 after purchasing an additional 38,974 shares during the period. Synovus Financial Corp boosted its holdings in shares of Lantheus by 2.6% during the first quarter. Synovus Financial Corp now owns 26,315 shares of the medical equipment provider's stock worth $2,568,000 after purchasing an additional 676 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Lantheus during the first quarter worth about $1,305,000. Finally, Penn Capital Management Company LLC boosted its holdings in shares of Lantheus by 11.5% during the first quarter. Penn Capital Management Company LLC now owns 146,903 shares of the medical equipment provider's stock worth $14,378,000 after purchasing an additional 15,109 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. B. Riley dropped their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the stock a "hold" rating in a report on Monday, August 11th. William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Mizuho lowered their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $105.50.

Lantheus Stock Down 1.1%

LNTH traded down $0.60 on Friday, hitting $54.90. The company had a trading volume of 1,028,454 shares, compared to its average volume of 2,626,054. The stock has a fifty day simple moving average of $69.20 and a 200-day simple moving average of $83.19. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The firm has a market capitalization of $3.73 billion, a P/E ratio of 14.60 and a beta of 0.15. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). The company had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business's quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.80 EPS. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,838,066 shares of company stock worth $384,430,031 in the last 90 days. Insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.